Media stories about Fluidigm (NASDAQ:FLDM) have trended somewhat positive this week, according to Accern. The research group rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Fluidigm earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned news articles about the medical research company an impact score of 45.1704638212317 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Separately, ValuEngine lowered Fluidigm from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 9th.
Shares of Fluidigm (FLDM) traded up $0.27 on Friday, reaching $6.59. The company had a trading volume of 191,724 shares, compared to its average volume of 210,497. The company has a market cap of $254.69, a P/E ratio of -2.96 and a beta of 3.37. The company has a debt-to-equity ratio of 5.00, a quick ratio of 2.46 and a current ratio of 3.02. Fluidigm has a 52-week low of $2.52 and a 52-week high of $8.04.
In related news, insider Levin Capital Strategies, L.P. acquired 60,000 shares of the stock in a transaction that occurred on Thursday, October 19th. The stock was purchased at an average cost of $4.55 per share, for a total transaction of $273,000.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last 90 days, insiders have purchased 503,068 shares of company stock valued at $2,679,781. 4.70% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This story was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://ledgergazette.com/2018/01/13/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-fluidigm-fldm-share-price.html.
Fluidigm Company Profile
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.